

Title:

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes (SURPASS-EARLY)

Principal Investigators:

Dr. John O'Mahony, Sarnia ON
Dr. Ronald Akhras, Montreal, QC
Dr. Nima Mirtorabi, Stouffville, ON
Dr. Michael Jones, Victoria, BC

Description of study:

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

Funding Source:

Sponsor Funded – Eli Lilly

Project Start Date:

November 1, 2022

Project End Date:

June 1, 2023

Eligibility:

Key Inclusion Criteria:

- Have, within the last 4 years, been diagnosed with T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
- Have HbA1c $\geq 7\%$ to $\leq 9.5\%$ as determined by the central laboratory.
- Have been on a stable treatment of metformin only at least 90 days preceding baseline
 - with the minimum effective dose of ≥ 1500 mg/day, but not higher than the maximum approved dose per country-specific label, or
 - < 1500 mg/day in case of intolerance of full therapeutic dose.

Ethics Approval:

Advarra IRB

Contact

If you would like to participate in this study, please contact:

Grant Hillar (Trial Management Group Inc.)

Email: Grant@tmginvestigators.com